Autonomous dysregulation of orthostatic disorders in young individuals engaged into manual work.

The authors analyzed changes of statistic, spectral and non-linear parameters of cardiac rhythm variability in response to active orthostasis test in young individuals engaged into manual work, and the results are compared with hemodynamic parameters. Evidence is that the patients with neurogenous fainting present sympathetic vasomotory regulation disorders even in young age; before clinical manifestation as orthostatic hypotension. In comparison with common tilt-test, spectral analysis of cardiac rhythm variability in active orthostatic test can be more useful to reveal early disorders of autonomous regulation.

[The novel method for selection of preparations for treatment of arterial hypertension based on spectral analysis of heart rhythm variability]. / Novyi sposob podbora preparatov dlia lecheniia arterial'noi gipertonii na osnove spektral'nogo analiza variabel'nosti ritma serdtsa.

AIM: To study spectral characteristics of heart rhythm in patients with arterial hypertension (AH) to select medication for hypertension and control over the treatment efficacy. MATERIAL AND METHODS: 35 AH patients were examined with general clinical methods and using spectral analysis of variability of heart rhythm (VHR). Five spectrograms were registered. Each of them contained three peaks: very low, low and high frequencies (VLF, LF and HF, respectively). Normal values of VLF, LF and HF were estimated on the basis of spectral values obtained in healthy subjects. After registration of spectral values all the patients were given at first placebo, than enalapril, one day after its discontinuation--mifedipine. At each stage VHR was recorded. Changes in the spectral indices were compared to changes in clinical symptoms. RESULTS: VLF proved most important for a rapid choice of adequate antihypertensive therapy. CONCLUSION: Normalization of VLF, LF and HF indicates adequacy of the choice of antihypertensive treatment.

A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network.

This randomized open-label trial of human immunodeficiency virus type 1-infected persons compared safety and efficacy for 38 patients receiving hydroxyurea/didanosine combination therapy with findings in 42 persons given didanosine monotherapy for 12 weeks, followed by 12 weeks of hydroxyurea/didanosine combination therapy for all patients. Week 12 on-treatment group comparisons showed a mean decrease in virus load between hydroxyurea/didanosine versus didanosine groups of -0.93 versus -0.74 log10 copies/mL (P=.20); a higher percentage of the hydroxyurea/didanosine group below the assay's detection limit (500 copies/mL), 29% versus 7% (P=.017); and median change in CD4 cells for the hydroxyurea/didanosine versus didanosine group of 0 versus 43 cells/mm3 (P=.045), although median change in CD4 percentage was similar (0.9% vs. 1.2%, P=.64). Week 24 virus load reductions and CD4 cell changes were similar in both groups. Intent-to-treat and on-treatment analyses showed similar results. The hydroxyurea/didanosine combination was well tolerated.